Findings from the randomized phase 3 Neo ALTTO trial in women with HER2-positive early breast cancer showed that the combination of lapatinib and trastuzumab significantly improved rates of pathological complete response compared with either drug alone. Here, ERBB2 is linked to breast cancer.